Robert Ticktin Sells 23,151 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) COO Robert Ticktin sold 23,151 shares of the business’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total value of $24,540.06. Following the sale, the chief operating officer directly owned 98,695 shares of the company’s stock, valued at approximately $104,616.70. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

PMV Pharmaceuticals Trading Up 10.0%

NASDAQ:PMVP opened at $1.21 on Friday. The firm’s fifty day simple moving average is $0.99 and its 200 day simple moving average is $1.19. PMV Pharmaceuticals, Inc. has a twelve month low of $0.81 and a twelve month high of $1.82. The firm has a market capitalization of $62.86 million, a price-to-earnings ratio of -1.03 and a beta of 1.49.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.03. On average, analysts predict that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a research report on Thursday, March 20th.

Institutional Investors Weigh In On PMV Pharmaceuticals

Several hedge funds have recently modified their holdings of PMVP. JPMorgan Chase & Co. lifted its position in PMV Pharmaceuticals by 2,282.8% during the 4th quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company’s stock worth $37,000 after acquiring an additional 23,559 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in PMV Pharmaceuticals in the fourth quarter valued at approximately $53,000. Squarepoint Ops LLC raised its stake in shares of PMV Pharmaceuticals by 68.7% during the fourth quarter. Squarepoint Ops LLC now owns 73,015 shares of the company’s stock valued at $110,000 after purchasing an additional 29,722 shares during the period. Northern Trust Corp lifted its position in shares of PMV Pharmaceuticals by 23.2% during the fourth quarter. Northern Trust Corp now owns 107,340 shares of the company’s stock worth $162,000 after purchasing an additional 20,190 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in shares of PMV Pharmaceuticals by 44.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company’s stock worth $305,000 after purchasing an additional 62,200 shares in the last quarter. 90.20% of the stock is currently owned by hedge funds and other institutional investors.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.